Home / Intelligence / Case Studies / Strategic Recommendations About Potential Actions to Shape Bone Health Policy
Trinity completed a detailed analogue assessment to understand how various stakeholders are involved in shaping health policies across markets.
Geographic Scope: 
Client Situation
The client wanted to identify best practices as well as the external stakeholders they should consider working with to efficiently shape global bone health policy.
Trinity’s Solution
Trinity conducted a systematic analogue disease area filtration to understand the disease areas where health policy development is most comparable to the bone health space.
Trinity then conducted exhaustive secondary research within each analogue disease area to understand the most relevant health policy shaping stakeholders, their actions, and consequent impact; leverage key learnings from each analogue disease area to inform bone health policy recommendations.
Deliverables
- Analogue selection and methodology
- High level executive summary explaining overall trends
- Analogue assessments for five disease areas of interest
- Recommendations for exploring partnerships in developing bone health policy
Project Outcomes & Impact
The client was able to understand the strategic actions they could take in order to shape bone health policy across several markets and define the success factors that drive stakeholder engagement in policy-shaping activities. The client was also able to develop compelling case studies in order to gather cross-functional buy-in.
Related Intelligence
Blog
Joint Clinical Assessment in the EU: What Life Sciences Companies Need to Know
March 2025 marked a pivotal moment for pharmaceutical and biotech companies operating in the European Union (EU) as the first two molecules began to proceed through the Joint Clinical Assessment (JCA) process. At a recent seminar hosted by Trinity Life Sciences, stakeholders gathered to explore the implications of this new regulatory framework and how to […]
Read More
Blog
Pricing and Access in Germany: Innovation and Strong Evidence Rewarded
Germany’s Medical Research Act (Medizinforschungsgesetz or MFG), which came into force on October 30, 2024, is a major legislative reform aimed at strengthening Germany’s position as an attractive environment for medical innovation and pharmaceutical development. The act provides for confidential negotiated drug pricing, incentives for local clinical trials, simplified clinical trial approvals and harmonization of […]
Read More
Blog
Seizing the Storm: Why Pharma Must Plan, Not Panic in Trump’s Second Term
The first 100 days of President Trump’s return to the White House have been anything but ordinary. With a true “Flood the Zone” strategy, there has been a flurry of executive orders, leadership reshuffles, and a re-assertion of executive power, which has signaled the administration is interested in seeing what policy options can “stick.” While […]
Read More